Skip to content

Updates: Retina

17th October, 2024

Transforming Drug Development with 3D Retina Models

Newcells Biotech Limited, a team of internationally recognised experts in the building and application of complex models of human tissues for drug discovery, was awarded £1m to deliver their…

Read update
5th May, 2023

ARVO Highlights

About the conference: ARVO The ARVO conference took place in the New Orleans Ernest N. Morial Convention Center.  With over 10 000 attendees, the venue was absolutely huge. If you…

Read update
iPSC-derived retinal pigment epithelial (RPE) cells
28th April, 2023

Latest innovation in retina models brings a fully characterised Retina Pigment Epithelium (RPE)

Why develop an RPE model? Retinal pigment epithelium (RPE) cells play a vital role in the retina by forming the outer blood-retinal barrier and maintaining photoreceptor and visual…

Read update
ADC, Antibody drug conjugate,
20th April, 2023

Antibody drug conjugates (ADCs) – the role of in vitro models in safety assessment

One the fastest growing approaches to treat cancer is the use of antibody drug conjugates (ADCs). Since the approval of the first antibody drug conjugate  in 2000,…

Read update
Accelerate preclinical testing
15th June, 2022

Gene therapy vectors: Preclinical testing with retinal organoids

Adeno Associated Virus (AAV) vectors have emerged as the most successful retinal gene therapy vectors following the FDA approval of Luxturna in 2017. This new gene therapy product is…

Read update
Retinal organoids
28th April, 2022

Retinal Organoids for Drug Discovery

Retinal diseases have been at the forefront of gene and cell therapy over the last 30 years with conditions such as macular degeneration and Stargardt disease likely to be…

Read update
1st August, 2024

Press Release: Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes

Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes,…

Read update
Rhys and collin at JSOT 2024
12th July, 2024

The Intensity of Innovation: Insights from the Japanese Society of Toxicology Conference

A Unique Exhibition-Poster Integration One striking feature of JSOT is how they seamlessly integrate exhibitions with poster sessions. Exhibitors and poster presenters are…

Read update
8th July, 2024

Press Release: Newcells Biotech appoints Emile Shaffu as Director of Sales

Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes,…

Read update
28th June, 2024

Newsletter June 2024

How does Newcells works with their clients? Listen to our CEO, Dr Mike Nicholds explaining. Webinar on demand: Moving compounds to IND using predictive retinal models. Our panel of experts…

Read update
11th June, 2024

Press Release : Newcells Biotech strengthens executive and US team with key appointments

Dr Valeria Chichagova appointed as Director of Technology, Dr Colin Brown as Chief Scientific Officer, and Professor Lyle Armstrong as Scientific Advisor New US commercial appointments also announced…

Read update
6th March, 2024

Biotech firm raises £2.3m for lab models that help avoid animal testing

The Newcastle-based company has secured funding from existing investors including the North East Venture Fund, supported by the European Regional Development Fund and managed by Mercia Ventures, Mercia’s own funds…

Read update

Get our latest updates straight to your inbox